The oxidant/antioxidant cell balance can by evaluated by several plasma and/or erythrocyte markers (20, 21)
As a biomarker, it is used in the diagnosis and treatment of growth disorders, has been implicated in the prognosis and diagnosis of several cancers, and is used to aid in the identification of athletic enhancement from growth hormone use
I am NOT advising you to follow my possibly questionable practice, but, when I knew we were going through Brexit I took note of the expiry dates of ampoules that were being issued at the time and chose to buy enough ampoules to last me for a year beyond their expiry date - working on the principle it might take a couple of years for the supply chain to work itself out and I didn't want to run out
Tas S et al
3.1.2 Other PEDs This group included other substances prohibited by WADA, such as non-approved substances (BPC-157) from Section S0, other anabolic agents (clenbuterol and SARMs) from Subsection S0, S1.2, peptide hormones and their releasing factors (AOD-9604, hGH 176-191, CJC-1295, ibutamoren, ipamorelin, and growth hormone-releasing peptide) from S2.2, growth factors and growth factor modulators (thymosin-4 and its derivative TB-500) from S2.3, beta-2 agonists (salbutamol and indacaterol) from S3, metabolic modulators (meldonium, GW1516, SR9009, SR9011, and insulins) from Section S4.4, and thyroid hormones
.png)
